

# Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Neisseria meningitidis, 2012



# **ABCs Areas**

California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia; Maryland; Minnesota; New Mexico; New York (15 county Rochester and Albany areas); Oregon; Tennessee (20 counties)

# **ABCs Population**

The surveillance areas represent 42,803,061 persons. Source: National Center for Health Statistics bridged-race vintage 2012 postcensal file

# **ABCs Case Definition**

Meningococcal disease: isolation of *Neisseria meningitidis* from normally sterile site in a resident of a surveillance area in 2012.

# **ABCs Methodology**

ABCs personnel routinely contacted all microbiology laboratories serving acute care hospitals in their area to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Serogrouping of meningococcal isolates was done at CDC and state laboratories. Regular laboratory audits assessed completeness of active surveillance and detected additional cases.

All rates of meningococcal disease were calculated using population estimates for 2012. For national estimates of cases, race- and age-specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the 2012 U.S. population for 49 states (excluding Oregon due to an outbreak of serogroup B disease). The Oregon reported cases were then added to obtain the national estimates. Cases with missing data, excluding ethnicity, were multiply imputed using the sequential regression imputation method.<sup>¶</sup>

#### **Reported ABCs Profiles**

Race	No.	(Rate <sup>*</sup> )
White	62	(0.19)
Black	11	(0.14)
Other	7	(0.21)
Total	80	(0.19)

\* Cases per 100,000 population for ABCs areas

	Cases	Deaths	
Syndrome	No. (%*)	No. (Rate <sup><math>\dagger</math></sup> )	
Meningitis	37 (46.3)	6 (16.2)	
Bacteremia without focus	22 (27.5)	2 (9.5)	

\* Percent of cases

<sup>†</sup> Deaths per 100 cases with known outcome

#### <sup>¶</sup> Surveillance Note

Missing race (n=14) data were multiply imputed using sequential regression imputation methods.

Serogroups
------------

				0 1				
Age		В		С		Y		<b>Other</b> <sup>‡</sup>
(years)	N	lo. (Rate <sup>*</sup> )	No	. (Rate <sup>*</sup>	) No	). (Rate <sup>*</sup>	) N	o. (Rate <sup>*</sup> )
< 1	6	(1.24)	0	(0.00)	1	(0.21)	2	(0.41)
1	2	(0.41)	0	(0.00)	0	(0.00)	0	(0.00)
2-4	2	(0.13)	1	(0.07)	0	(0.00)	0	(0.00)
5-17	1	(0.02)	0	(0.00)	3	(0.05)	0	(0.00)
18-34	9	(0.10)	6	(0.07)	2	(0.02)	0	(0.00)
35-49	1	(0.01)	2	(0.03)	3	(0.04)	2	(0.03)
50-64	1	(0.01)	1	(0.01)	3	(0.04)	1	(0.01)
$\geq 65$	1	(0.02)	0	(0.00)	7	(0.14)	0	(0.00)
Total <sup>†</sup>	23	(0.06)	10	(0.03)	19	(0.05)	5	(0.01)

Unknown serogroup (n=2) distributed amongst known

\*Cases per 100,000 population for ABCs areas excluding Oregon

<sup>†</sup> All rates exclude Oregon. Rates including Oregon are serogroup B 0.08, serogroup C 0.04, serogroup Y 0.06, and serogroup Other 0.01 cases per 100,000 population for ABCs areas

<sup>‡</sup> Other includes serogroup W-135 and non-groupables

# Rates of Meningococcal Disease in Adolescents and Young Adults $^{\dagger}$

	Overall Serogroups	C/Y/W-135 Serogroups
Age (years)	No. (Rate <sup>*</sup> )	No. (Rate <sup>*</sup> )
11-17	4 (0.11)	3 (0.08)
18-22	5 (0.18)	2 (0.07)

\* Cases per 100,000 population for ABCs areas excluding Oregon

<sup>†</sup> All rates exclude Oregon. Rates including Oregon are, for 11-17 year olds, overall serogroups 0.15 and serogroup C/Y/W-135 0.13; for 18-22 year olds, overall serogroups 0.27 and serogroup C/Y/W-135 0.10 cases per 100,000 population for ABCs areas

# National Estimates for Disease<sup>¥</sup>

Cases:	480	(0.15/100,000)
Deaths:	75	(0.02/100,000)

<sup>¥</sup> In 2012, 551 cases of meningococcal disease (probable and confirmed) were reported to the National Notifiable Disease Surveillance System (incidence 0.18/100,000 population)

#### Healthy People 2020 Update

Objective: Reduce the incidence of meningococcal disease to 0.3 per 100,000 population.

2020 Objective	2012 Rate <sup>*</sup>	
0.3/100,000	0.15/100,000	
<sup>k</sup> Cases per 100,000 U.S. population		

# For more information, visit our web site:

http://www.cdc.gov/abcs

#### Citation

Centers for Disease Control and Prevention. 2013. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2012. Available via the Internet:

http://www.cdc.gov/abcs/reports-findings/survreports/mening12.pdf